TY - JOUR
T1 - The role of depression pharmacogenetic decision support tools in shared decision making
AU - Arandjelovic, Katarina
AU - Eyre, Harris A.
AU - Lenze, Eric
AU - Singh, Ajeet B.
AU - Berk, Michael
AU - Bousman, Chad
N1 - Funding Information:
Acknowledgements MB is currently supported by a NHMRC Senior Principal Research Fellowship 1059660.
Publisher Copyright:
© 2017, Springer-Verlag GmbH Austria.
PY - 2019/1/21
Y1 - 2019/1/21
N2 - Patients discontinue antidepressant medications due to lack of knowledge, unrealistic expectations, and/or unacceptable side effects. Shared decision making (SDM) invites patients to play an active role in their treatment and may indirectly improve outcomes through enhanced engagement in care, adherence to treatment, and positive expectancy of medication outcomes. We believe decisional aids, such as pharmacogenetic decision support tools (PDSTs), facilitate SDM in the clinical setting. PDSTs may likewise predict drug tolerance and efficacy, and therefore adherence and effectiveness on an individual-patient level. There are several important ethical considerations to be navigated when integrating PDSTs into clinical practice. The field requires greater empirical research to demonstrate clinical utility, and the mechanisms thereof, as well as exploration of the ethical use of these technologies.
AB - Patients discontinue antidepressant medications due to lack of knowledge, unrealistic expectations, and/or unacceptable side effects. Shared decision making (SDM) invites patients to play an active role in their treatment and may indirectly improve outcomes through enhanced engagement in care, adherence to treatment, and positive expectancy of medication outcomes. We believe decisional aids, such as pharmacogenetic decision support tools (PDSTs), facilitate SDM in the clinical setting. PDSTs may likewise predict drug tolerance and efficacy, and therefore adherence and effectiveness on an individual-patient level. There are several important ethical considerations to be navigated when integrating PDSTs into clinical practice. The field requires greater empirical research to demonstrate clinical utility, and the mechanisms thereof, as well as exploration of the ethical use of these technologies.
KW - Adherence
KW - Antidepressants
KW - Decision support tool
KW - Pharmacogenetics
KW - Psychoeducation
KW - Shared decision making
KW - Therapeutic alliance
UR - http://www.scopus.com/inward/record.url?scp=85032497594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032497594&partnerID=8YFLogxK
U2 - 10.1007/s00702-017-1806-8
DO - 10.1007/s00702-017-1806-8
M3 - Article
C2 - 29082439
AN - SCOPUS:85032497594
SN - 0300-9564
VL - 126
SP - 87
EP - 94
JO - Journal of Neural Transmission
JF - Journal of Neural Transmission
IS - 1
ER -